GATESHEAD HEALTH NHS FOUNDATION TRUST

Yaqrit Secures £2.2 Million NIHR Grant for Pivotal DIALIVE Liver Support Device Trials

2 months ago

• Yaqrit has received a £2.2 million ($2.85 million) grant from the UK's National Institute for Health and Care Research to fund pivotal trials of its DIALIVE liver support device across 13 UK centers. • The DIALIVE device treats Acute-on-Chronic Liver Failure (ACLF) by removing disease-causing toxins from blood and exchanging dysfunctional albumin, showing twice the resolution rate compared to standard care in previous studies. • The randomized trial will enroll approximately 70 high-risk ACLF grade 2-3 patients, with results expected in Q1 2027, potentially offering new hope for a condition that carries 40-80% mortality within 28 days.

Gilead's Seladelpar Receives European Commission Approval for Primary Biliary Cholangitis

5 months ago

• The European Commission has granted conditional marketing authorization for Gilead's seladelpar for primary biliary cholangitis (PBC). • Seladelpar is approved for use in combination with UDCA for those with inadequate response, or as a monotherapy for those who cannot tolerate UDCA. • The approval is based on Phase 3 RESPONSE trial data, showing significant improvements in biochemical response and pruritus reduction. • This decision provides a new treatment option for PBC patients in Europe, addressing a critical unmet need.

DaRe2THINK Clinical Trial Platform Reaches 1,000 NHS Patient Milestone

6 months ago

• The DaRe2THINK platform, designed to integrate clinical trials within general practice, has successfully recruited 1,000 NHS patients, marking a significant milestone. • The platform screens routine health records of over 13 million NHS patients to identify suitable candidates for trials, focusing on preventing strokes, blood clots, and vascular dementia in atrial fibrillation patients. • Recent innovations have led to a 'number needed to invite' of 5.3, indicating high efficiency in patient recruitment compared to other clinical trials. • DaRe2THINK aims to broaden research participation within the NHS and contribute to the UK's life science strategy for improved health and economic growth.

Acticor Biotech Repositions Glenzocimab for Myocardial Infarction Treatment

7 months ago

• Acticor Biotech is focusing on myocardial infarction with glenzocimab, encouraged by expert feedback on its potential in STEMI treatment. • The LIBERATE phase 2b study, in partnership with the University of Birmingham, is ongoing, assessing glenzocimab's impact on infarct size in 212 STEMI patients. • A new phase 2 study, GLORIA, is being prepared to evaluate glenzocimab in approximately 300 STEMI patients, aiming for Phase 3 readiness by 2027. • Patient recruitment for GLORIA could begin in Q1 2025, contingent on the company's financial status and ongoing receivership procedure.

Current Clinical Trials in Traumatic Brain Injury

3 years ago

A comprehensive review of clinical trials for traumatic brain injury (TBI) highlights the ongoing search for effective treatments, focusing on drugs like amantadine, botulinum toxin A, and tranexamic acid. Despite numerous trials, the variability in study outcomes underscores the need for careful trial design and patient stratification.